TRIGUARD™

The only embolic cerebral protection device designed to provide full coverage to all brain territories, to minimize the risk of cerebral damage during TAVR and other cardiovascular procedures.
read more

EMBOLIC CEREBRAL PROTECTION

Keystone Heart is focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, atrial fibrillation ablation and other structural heart
read more

BRAIN INJURY AND RESERVE

Cerebral function is the essence of quality of life; its preservation throughout medical procedures is a key component to procedural success and patient care.
read more

Data Presented at ACC Demonstrates Benefits of Keystone Heart’s TriGuard™ Cerebral Protection Device during TAVR

Keystone Heart today announced that its CE marked TriGuard™ Cerebral Protection Device has improved in-hospital safety outcomes and cognitive scores at discharge during Transcatheter Aortic Valve Replacement (TAVR). Based on changes in NIH Stroke Scale, patients protected with TriGuard had 10% absolute reduction in stroke (4.9% vs. 14.3%). Minor strokes were under detected without detailed NIHSS assessment.

ABOUT KEYSTONE HEART

Keystone Heart develops and manufactures embolic cerebral protection devices to reduce the risk of stroke, neurocognitive decline and dementia caused by brain emboli associated with cardiovascular procedures.
The Company is focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, surgical valve replacement, atrial fibrillation ablation and other cardiovascular procedures. 

Cerebral function is the essence of quality of life. Preserving brain reserve throughout medical procedures is a key component to procedural success and patient care.
read more
The TriGuard Cerebral Protection Device is not yet commercially available in the USA.